Reimagining the future of healthcare
LENA / Epilepsy Community Advocate
Spotlight: uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
Press Releases
Subscribe to receive breaking news alerts about uniQure.
Subscribe-
-
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
-
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress